title: Lower doses of recombinant porcine factor VIII maintain excellent haemostatic efficacy.
authors.affiliation: Department of Medicine, Division of Hematology Oncology, University of North Carolina, Chapel Hill, NC, USA.
authors.forename: K
authors.initials: K
authors.lastname: Martin
authors.affiliation: Department of Medicine, Division of Hematology Oncology, University of North Carolina, Chapel Hill, NC, USA.
authors.forename: R
authors.initials: R
authors.lastname: Kasthuri
authors.affiliation: Department of Medicine, Division of Hematology Oncology, University of North Carolina, Chapel Hill, NC, USA.
authors.forename: M J
authors.initials: MJ
authors.lastname: Mooberry
authors.affiliation: Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
authors.forename: S-L
authors.initials: SL
authors.lastname: Chen
authors.affiliation: Department of Medicine, Division of Hematology Oncology, University of North Carolina, Chapel Hill, NC, USA.
authors.forename: N S
authors.initials: NS
authors.lastname: Key
authors.affiliation: Department of Medicine, Division of Hematology Oncology, University of North Carolina, Chapel Hill, NC, USA.
authors.forename: A D
authors.initials: AD
authors.lastname: Ma
mesh_terms: D000368:Aged; D000818:Animals; D005169:Factor VIII / Q000008:administration & dosage*; D005260:Female; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy*; D006487:Hemostasis; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage; D013552:Swine
chemical_list: D006490:Hemostatics; D011994:Recombinant Proteins; D005169:Factor VIII